[go: up one dir, main page]

WO2007010509A3 - Controlled release pharmaceutical composition comprising alpha-adrenergic antagonist and muscarinic antagonist - Google Patents

Controlled release pharmaceutical composition comprising alpha-adrenergic antagonist and muscarinic antagonist Download PDF

Info

Publication number
WO2007010509A3
WO2007010509A3 PCT/IB2006/052539 IB2006052539W WO2007010509A3 WO 2007010509 A3 WO2007010509 A3 WO 2007010509A3 IB 2006052539 W IB2006052539 W IB 2006052539W WO 2007010509 A3 WO2007010509 A3 WO 2007010509A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist
release pharmaceutical
alpha
pharmaceutical composition
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/052539
Other languages
French (fr)
Other versions
WO2007010509A2 (en
Inventor
Rajesh Shear
Pratik Kumar
Rajeev Singh Raghuvanshi
Ashok Rampal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2007010509A2 publication Critical patent/WO2007010509A2/en
Publication of WO2007010509A3 publication Critical patent/WO2007010509A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention pertains to orally administered controlled-release pharmaceutical compositions comprising a combination of α-adrenergic antagonists and muscarinic receptor antagonists and processes for the preparation of the composition.
PCT/IB2006/052539 2005-07-22 2006-07-24 Controlled release pharmaceutical composition comprising alpha-adrenergic antagonist and muscarinic antagonist Ceased WO2007010509A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1933DE2005 2005-07-22
IN1933/DEL/2005 2005-07-22

Publications (2)

Publication Number Publication Date
WO2007010509A2 WO2007010509A2 (en) 2007-01-25
WO2007010509A3 true WO2007010509A3 (en) 2007-08-09

Family

ID=37669222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/052539 Ceased WO2007010509A2 (en) 2005-07-22 2006-07-24 Controlled release pharmaceutical composition comprising alpha-adrenergic antagonist and muscarinic antagonist

Country Status (1)

Country Link
WO (1) WO2007010509A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1123705A1 (en) * 2000-02-09 2001-08-16 Pfizer Products Inc. Pharmaceutical combinations for treating lower urinary tract disfunctions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1123705A1 (en) * 2000-02-09 2001-08-16 Pfizer Products Inc. Pharmaceutical combinations for treating lower urinary tract disfunctions
US20010044438A1 (en) * 2000-02-09 2001-11-22 Wyllie Michael G. Pharmaceutical combinations

Also Published As

Publication number Publication date
WO2007010509A2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
PL2054411T3 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2008005345A3 (en) Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions
WO2006086488A3 (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
ATE427740T1 (en) SEDATING AND NON-SEDATING ANTIHISTAMINE COMPOSITIONS
TN2011000282A1 (en) Alkaloid aminoester derivatives and medicinal composition thereof
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
MY143581A (en) Carboxamide derivatives as muscarinic receptor antagonists
WO2007120284A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2008072053A8 (en) Substituted arylpyrazoles
UA92670C2 (en) Pyrazoline compounds as mineralocorticoid receptor antagonists , pharmaceutical use thereof, composition based thereon
WO2007073432A3 (en) Piperidine derivatives and methods of use
WO2007050802A3 (en) Novel opioid antagonists
WO2007044796A3 (en) Pyridazinone compounds as calcilytics
WO2008001201A3 (en) Pharmaceutical compositions of clopidogrel
CL2007003483A1 (en) COMPOUNDS DERIVED FROM INDOL-2-IL-CARBONIL-ESPIRO-PIPERIDINA, ANTAGONISTS OF THE V1A RECEIVER; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF HYPERTENSION, DESMENO
WO2005082893A3 (en) Histamine h3 receptor antagonists, preparation and therapeutic uses
CL2007003556A1 (en) COMPOUNDS DERIVED FROM 6- (PIPERIDIN-4-ILAMINO) PIRIDAZIN-3-CARBONITRILS, ANTAGONISTS OF THE DOPAMINE 2 RECEPTOR OF RAPIDA DISOCIACION; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE
WO2007114855A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007067875A3 (en) Pyridinyl sulfonamide modulators of chemokine receptors
BRPI0821909A2 (en) piperidine derivative
WO2010131192A3 (en) Novel oxazolidinone derivatives and their use as orexin receptor antagonists
WO2009034432A3 (en) Novel compounds active as muscarinic receptor antagonists

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06780193

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06780193

Country of ref document: EP

Kind code of ref document: A2